Skip Main Navigation
Page Content
This event has ended

Challenging the Science Publishing Status Quo

F1000Research

Monday, 22 April 2013 from 17:30 to 20:30 (EDT)

Challenging the Science Publishing Status Quo

Ticket Information

Type End Quantity
Standard Ended Free  
Press Ended Free  

Who's Going

Loading your connections...

Share Challenging the Science Publishing Status Quo

Event Details

UPDATE: Our thoughts are with everyone affected by the tragic events surrounding the Boston Marathon on Monday. Please note that the F1000Research event is continuing as planned, as is the Experimental Biology meeting. We hope to see you there.

_______________________


Challenging the Science Publishing Status Quo
F1000Research Sets New Standards for Transparency through Open Science Publishing

Coinciding with the Experimental Biology meeting in Boston, but open to delegates and non-delegates alike, this event brings together leading minds in life sciences to discuss the benefits of Open Science publishing for the research community. The discussion will cover the significant issues currently affecting the way research findings are published including:

  • The importance of rapid publication and the negative impact of delays;
  • The benefits of a completely open and transparent peer review;
  • The importance of open publication of all data to enable reuse and the testing of reproducibility by others;
  • The implications of the move towards open access (and full CC-BY access) by governments and funders; 
  • The benefits of publishing small science findings, null/negative/replication results, and other non-standard studies.
  • The distinguished list of speakers from the scientific community include:


Vitek Tracz: Chairman and Founder, F1000, and a pioneering supporter of Open Access

Steven Hyman: Distinguished Service Professor of Stem Cell and Regenerative Biology and Scholar in Residence, Broad Institute, Harvard University and MIT (and past-Provost, Harvard University)

Keith Flaherty: Director of Developmental Therapeutics, Massachusetts Cancer Center

Gary Borisy: Biophysics, Senior Scientist & President Emeritus, Marine Biological Laboratory, Woods Hole, MA

Lawrence Kane: Associate Professor of Immunology, Director of Immunology Graduate Program, University of Pittsburgh

Sue Griffin: Dillard Professor and Vice Chairman, Donald W. Reynolds Dept of Geriatrics, University of Arkansas for Medical Sciences

Further details will be available soon.


About F1000Research
F1000Research is the original open access journal for life scientists that offers immediate publication, transparent peer review (post-publication) and full data deposition and sharing. The journal accepts all scientifically sound articles, including single findings, case reports, protocols, replications, null/negative results and more traditional articles. F1000Research is published by U.K. based Faculty of 1000 (F1000).

See all members of the Advisory Panel at:
http://f1000research.com/advisory-panel

And all members of the Editorial Board at:
http://f1000research.com/editorial-board

Author guidelines:
http://f1000research.com/author-guidelines

Do you have questions about Challenging the Science Publishing Status Quo? Contact F1000Research

When & Where


Boston Convention Center, Room #52A
415 Summer Street
Boston, MA 02210

Monday, 22 April 2013 from 17:30 to 20:30 (EDT)


  Add to my calendar

Organiser

F1000Research

F1000Research is an open science publishing platform for life scientists that offers immediate open access publication, transparent post-publication peer review by invited referees, and full data deposition and sharing. F1000Research accepts all scientifically sound articles, including single findings, case reports, protocols, replications, null/negative results, and more traditional articles.

  Contact the Organiser

Interested in hosting your own event?

Join millions of people on Eventbrite.

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.